1,301
Participants
Start Date
January 16, 2015
Primary Completion Date
January 6, 2017
Study Completion Date
January 12, 2017
DS-5565
DS-5565 15 mg QD or BID; tablet for oral use
Pregabalin
Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
Placebo tablet
Placebo tablet for oral use, matching DS-5565 tablet
Placebo capsule
Placebo capsule for oral use, matching pregabalin capsule
Vienna
Senftenberg
Brooklyn
Richmond
Marietta
Edgewater
DeLand
Orlando
Vero Beach
Hialeah
Lauderdale Lakes
Boca Raton
Largo
Birmingham
Franklin
Chattanooga
Knoxville
Middleburg Heights
Ann Arbor
Minot
New Orleans
Houston
Austin
Phoenix
Lakewood
Lomita
Northridge
Covina
Upland
National City
El Cajon
Huntington Beach
Bellevue
Richland
Owensboro
Huntsville
Scottsdale
Tempe
Tucson
Anaheim
Encino
Los Angeles
Oceanside
Sacramento
Walnut Creek
Fort Lauderdale
Fort Myers
Maitland
Miami
Sunrise
Tamarac
Tampa
West Palm Beach
Winter Haven
Winter Park
Dawsonville
Smyrna
Chicago
Evansville
Granger
Overland Park
Lake Charles
Frederick
Brockton
North Dartmouth
Ann Arbor
Lansing
Rochester Hills
Florissant
Hazelwood
O'Fallon
Bellevue
Newington
Albuquerque
Cedarhurst
Rochester
Charlotte
Raleigh
Winston-Salem
Cincinnati
Columbus
Dayton
Oklahoma City
Portland
Altoona
Media
Wyomissing
Greenville
Mt. Pleasant
Memphis
Lake Jackson
San Antonio
Norfolk
CABA
La Plata
Lanús
Mar del Plata
Quilmes
San Fernando
Rosario
Córdoba
San Miguel de Tucumán
Santa Fe
Klagenfurt
Minsk
Vitebsk
Brussels
Edegem
Gozée
Oostham
Antofagasta
Providencia
Puerto Varas
Viña del Mar
Barranquilla
Bogotá
Haifa
Kfar Saba
Ramat Gan
Tel Aviv
Cuautitlán Izcalli
Durango
Guadalajara
León
Mexico City
Elblag
Gdansk
Katowice
Krakow
Lublin
Nadarzyn
Nowa Sól
Torun
Tychy
Warsaw
Aveiro
Braga
Guimarães
Lisbon
Ponte de Lima
Porto
Vila Nova de Gaia
Ljubljana
Slovenj Gradec
Alicante
Barcelona
Elche
Granada
Guadalajara
Madrid
Santiago de Compostela
Seville
Geneva
Sankt Gallen
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
Daiichi Sankyo
INDUSTRY